Jafron Biomedical Co.,Ltd. (SHE: 300529)

Jafron Biomedical Co.,Ltd. Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019
Operating Revenue	2,399	1,919	2,487	2,671	1,946	1,429
Other Revenue	6.55	3.42	4.54	4.5	4.64	2.61
Revenue	2,406	1,922	2,491	2,675	1,951	1,432
Revenue Growth (YoY)	23.42%	-22.84%	-6.88%	37.15%	36.24%	40.86%
Cost of Revenue	479.66	385.42	440.36	402.12	288	197.44
Gross Profit	1,926	1,537	2,051	2,273	1,663	1,234
Selling, General & Admin	822.31	793.36	838.78	729.46	587.45	537.15
Research & Development	243.54	245.38	253.91	173.77	80.76	68.45
Other Operating Expenses	53.34	24.61	33.72	39.56	28.24	22.39
Operating Expenses	1,119	1,054	1,124	949.55	697.27	629.88
Operating Income	806.99	482.98	926.66	1,324	965.51	604.5
Interest Expense	-61.67	-54.33	-36.04	-8.91	-	-
Interest & Investment Income	77.28	87.96	63.79	56.5	44.01	44.21
Currency Exchange Gain (Loss)	1.16	1.22	1.07	-0.81	-0.37	0.13
Other Non Operating Income (Expenses)	5.87	-2.12	-0.5	-5.34	-2.36	-0.16
EBT Excluding Unusual Items	829.62	515.71	954.97	1,365	1,007	648.67
Impairment of Goodwill	-25.61	-25.61	-6.26	-	-	-
Gain (Loss) on Sale of Investments	5.8	-	-0.01	0.01	-	-
Gain (Loss) on Sale of Assets	2.83	6.72	0.86	0.98	-	-
Asset Writedown	-1.49	-1.46	-1.61	-1.15	-0.48	-1.35
Other Unusual Items	41.06	25.66	68.85	42.14	25.64	23.96
Pretax Income	852.21	521.02	1,017	1,407	1,032	671.28
Income Tax Expense	150.93	95.3	135.86	211.38	158.95	102.59
Earnings From Continuing Operations	701.28	425.72	880.95	1,196	873	568.69
Minority Interest in Earnings	10.21	10.77	8.62	0.97	2.24	2.13
Net Income	711.49	436.49	889.56	1,197	875.24	570.82
Net Income to Common	711.49	436.49	889.56	1,197	875.24	570.82
Net Income Growth	69.84%	-50.93%	-25.67%	36.74%	53.33%	42.00%
Shares Outstanding (Basic)	798	794	794	803	796	793
Shares Outstanding (Diluted)	798	794	794	803	810	793
Shares Change (YoY)	-0.32%	-0.08%	-1.12%	-0.89%	2.22%	0.68%
EPS (Basic)	0.89	0.55	1.12	1.49	1.10	0.72
EPS (Diluted)	0.89	0.55	1.12	1.49	1.08	0.72
EPS Growth	70.39%	-50.89%	-24.83%	37.96%	50.00%	41.04%
Free Cash Flow	926.5	669.49	407.91	712	600.37	362.82
Free Cash Flow Per Share	1.16	0.84	0.51	0.89	0.74	0.46
Dividend Per Share	0.400	0.400	0.670	0.900	0.660	0.474
Dividend Growth	-40.30%	-40.30%	-25.56%	36.36%	39.33%	50.00%
Gross Margin	80.06%	79.95%	82.32%	84.97%	85.24%	86.21%
Operating Margin	33.54%	25.12%	37.19%	49.48%	49.49%	42.22%
Profit Margin	29.57%	22.71%	35.70%	44.73%	44.87%	39.87%
Free Cash Flow Margin	38.51%	34.83%	16.37%	26.61%	30.78%	25.34%
EBITDA	908.02	571.49	995.72	1,373	1,002	634.29
EBITDA Margin	37.74%	29.73%	39.97%	51.32%	51.38%	44.30%
D&A For EBITDA	101.03	88.51	69.07	49.25	36.73	29.79
EBIT	806.99	482.98	926.66	1,324	965.51	604.5
EBIT Margin	33.54%	25.12%	37.19%	49.48%	49.49%	42.22%
Effective Tax Rate	17.71%	18.29%	13.36%	15.02%	15.40%	15.28%
Revenue as Reported	2,406	1,922	2,491	2,675	1,951	1,432

Source: S&P Capital IQ. Standard template. Financial Sources.